| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CRYZL1 |
| Uniprot No | O95825 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-349aa |
| 氨基酸序列 | MKGLYFQQSS TDEEITFVFQ EKEDLPVTED NFVKLQVKAC ALSQINTKLL AEMKMKKDLF PVGREIAGIV LDVGSKVSFF QPDDEVVGIL PLDSEDPGLC EVVRVHEHYL VHKPEKVTWT EAAGSIRDGV RAYTALHYLS HLSPGKSVLI MDGASAFGTI AIQLAHHRGA KVISTACSLE DKQCLERFRP PIARVIDVSN GKVHVAESCL EETGGLGVDI VLDAGVRLYS KDDEPAVKLQ LLPHKHDIIT LLGVGGHWVT TEENLQLDPP DSHCLFLKGA TLAFLNDEVW NLSNVQQGKY LCILKDVMEK LSTGVFRPQL DEPIPLYEAK VSMEAVQKNQ GRKKQVVQF |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于 **CRYZL1重组蛋白** 的3篇代表性文献信息及简要摘要概括：
---
1. **文献名称**: *"Recombinant expression and functional characterization of human CRYZL1 in Escherichia coli"*
**作者**: Zhang Y, et al.
**摘要**: 本研究成功在大肠杆菌中表达并纯化了人源CRYZL1重组蛋白，验证了其酶活性(如氧化还原酶活性)，并发现其可能通过调控ROS水平参与细胞应激反应。
---
2. **文献名称**: *"CRYZL1 interacts with γ-crystallin and modulates lens transparency: Implications for cataract formation"*
**作者**: Liu H, et al.
**摘要**: 通过重组CRYZL1蛋白与γ-晶状体蛋白的体外互作实验，揭示CRYZL1可能通过稳定晶状体蛋白结构维持眼部透明性，其功能缺失可能与白内障发生相关。
---
3. **文献名称**: *"Proteomic analysis of CRYZL1 in hepatocellular carcinoma: A potential therapeutic target"*
**作者**: Wang X, et al.
**摘要**: 利用重组CRYZL1蛋白进行肝癌细胞功能研究，发现其过表达抑制肿瘤细胞增殖和迁移，提示CRYZL1可能作为肝癌治疗的分子靶点。
---
**备注**：以上文献为示例性内容，实际文献需通过PubMed、Web of Science等数据库检索。如需具体文章，建议使用关键词 **"CRYZL1 recombinant protein"** 或 **"CRYZL1 expression and function"** 进一步查找。
**Background of CRYZL1 Recombinant Protein**
CRYZL1 (Crystallin Zeta-Like 1) is a member of the ζ-crystallin family, a subgroup of NAD(P)H-dependent quinone oxidoreductases. It shares structural and functional similarities with other crystallin proteins, which are traditionally associated with maintaining lens transparency in the eye. However, CRYZL1 exhibits broader tissue expression, including the liver, brain, and testis, suggesting roles beyond ocular physiology.
The protein is encoded by the *CRYZL1* gene, located on human chromosome 19. and functions as a cytoplasmic enzyme involved in redox regulation and detoxification. It catalyzes the reduction of quinones and other reactive carbonyl compounds using NADPH as a cofactor, thereby mitigating oxidative stress and protecting cellular components from damage. This activity links CRYZL1 to metabolic pathways and cellular defense mechanisms.
Recombinant CRYZL1 is produced via heterologous expression systems (e.g., *E. coli* or mammalian cells) to study its biochemical properties, structure-function relationships, and interactions with substrates or inhibitors. Its purified form enables research into enzymatic kinetics, substrate specificity, and potential therapeutic applications. Notably, CRYZL1 has been implicated in neurodegenerative diseases, cancer, and cataracts, with studies exploring its role in modulating oxidative stress in pathological contexts.
As a research tool, recombinant CRYZL1 aids in drug discovery, particularly in screening small molecules targeting quinone metabolism or oxidative stress pathways. Its structural homology to other crystallins also makes it a model for studying protein aggregation disorders. Ongoing research aims to clarify its physiological significance and therapeutic potential in human diseases.
×
